首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

2047000

抗體藥物複合體市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Types, By Application, By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球抗體藥物複合體(ADC) 市場預計將從 2025 年的 83.9 億美元成長到 2031 年的 121.8 億美元，複合年成長率為 6.41%。

抗體藥物複合體（ADC）是一種先進的標靶免疫療法，由單株抗體透過化學鍵與細胞毒性有效載荷偶聯而成，其設計旨在選擇性地清除癌細胞，同時最大限度地減少對健康組織的損傷。這項市場擴張的主要促進因素是全球癌症發生率的上升、對能夠降低全身毒性的精準醫療需求的成長，以及偶聯技術的持續創新。根據美國癌症協會預測，到2024年，美國預計將新增約200萬例癌症病例，凸顯了對有效標靶治療方法的迫切需求。

市場概覽
預測期	2027-2031
市場規模：2025年	83.9億美元
市場規模：2031年	121.8億美元
複合年成長率：2026-2031年	6.41%
成長最快的細分市場	單株抗體
最大的市場	北美洲

然而，全球抗體藥物複合體（ADC）市場成長面臨的主要障礙是其生產所需的複雜技術及巨額資本投入。 ADC的生產需要高度專業的隔離設施，以安全處理強效細胞毒性物質，同時確保生物成分的穩定性，這給供應鏈帶來了獨特的挑戰。這些嚴格的生產要求往往導致生產成本增加和物流限制，可能延緩產品上市時間，並限制更多患者獲得治療，尤其是在對成本敏感的地區。

市場促進因素

戰略聯盟、併購和許可協議的顯著增加是推動全球抗體藥物複合體（ADC）市場快速發展的主要催化劑。大型製藥企業正積極收購處於臨床階段的生物技術公司，以將先進的連接子技術和新一代有效載荷整合到其產品組合中，從而降低早期研發風險。例如，2024年4月，Genmab A/S宣布達成最終協議，將以18億美元的現金交易收購ProfoundBio，旨在取得其尖端ADC產品組合的權益。這一趨勢凸顯了該行業對非內部成長策略的依賴，以快速擴大生產能力並確保未來商業化所需的關鍵智慧財產權。

同時，治療適應症的擴展，將固體癌納入其中，從根本上改變了市場潛力，而傳統上，骨髓惡性腫瘤一直佔據主導地位。監管機構正擴大批准標靶偶聯藥物用於治療卵巢和乳癌等複雜疾病，這主要得益於令人信服的臨床數據，這些數據表明，與標準化療相比，標靶偶聯藥物具有更優的療效。艾伯維公司於2024年3月宣布，核准ELAHERE核准，專門用於治療葉酸受體α陽性、含鉑類藥物抗藥性的上皮性卵巢、輸卵管癌或原發性腹膜癌患者。Astra Zeneca公司的一份報告也印證了這些固體癌療法的巨大商業性潛力。該報告顯示，其旗艦總合Enhertu在2024年前九個月的銷售額達到了27.29億美元。

市場挑戰

抗體藥物複合體生產固有的技術複雜性和高昂的財務成本，對市場擴張構成了重大障礙。這些先進療法的生產需要將生物抗體與強效化療藥物精確偶聯，這個過程需要高度專業化的隔離設施，以確保安全性和產品穩定性。這些嚴格的要求轉化為大量的資本投資和營運成本，限制了能夠處理如此複雜生產的工廠數量，並經常導致供應鏈瓶頸和產品交付延遲。

高昂的生產成本直接影響這些療法的最終價格，限制了醫療預算有限的市場獲得這些療法的機會。這種經濟壓力阻礙了新治療方法商業性獲利能力的速度。抗體學會的數據顯示，截至2024年，全球有超過150種抗體藥物複合體）處於積極的臨床開發階段，足以說明這項物流瓶頸的嚴重性。如此眾多的候選藥物給現有的專業生產能力帶來了沉重的負擔，進一步加劇了生產延誤，並阻礙了整體市場成長。

市場趨勢

抗體藥物複合體(ADC) 向非腫瘤治療領域的拓展，標誌著市場的一個變革性轉折點，其關注點從傳統的癌症治療轉向應對複雜的自體免疫疾病和發炎性疾病。研發人員正策略性地利用 ADC 技術的精準性，將強效免疫調節劑直接遞送至致病性免疫細胞，從而最大限度地降低廣譜免疫抑制劑通常伴隨的全身毒性。這種策略多元化在近期旨在獲取用於非癌症適應症的新型偶聯平台的高價值許可協議中得到了清晰的體現。例如，根據 Fierce Biotech 於 2025 年 9 月報道，Vertex Pharmaceuticals 與 Enlaza 達成了一項價值超過 20 億美元的多靶點藥物研發協議，該協議將專門開發用於自體免疫疾病的下一代小分子藥物偶聯物，凸顯了企業對這一新興治療領域的堅定商業性承諾。

同時，雙特異性抗體藥物複合體（BsADCs）的出現顯著提升了市場的技術能力，使其能夠同時靶向兩種不同的腫瘤相關抗原，或同一抗原上的不同表位。這種創新的雙標靶化機制不僅提高了腫瘤選擇性和體內攝取率，而且有望克服單特異性藥物中常見的抗藥性機制，例如抗原流失和低表達。隨著研發人員致力於將首批雙特異性療法商業化，該療法的臨床開發正在迅速推進。 2025年8月，《醫藥技術》雜誌報道稱，有四種雙特異性抗體藥物複合體候選藥物正在積極進行III期臨床試驗，這意味著它們可能很快就會獲得監管部門的批准並上市。

The Global Antibody Drug Conjugates Market is projected to grow from USD 8.39 Billion in 2025 to USD 12.18 Billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 6.41%. Antibody Drug Conjugates (ADCs) are sophisticated targeted immunotherapies that comprise a monoclonal antibody linked via a chemical bond to a cytotoxic payload, meticulously engineered to selectively eliminate tumor cells while minimizing harm to healthy tissues. This market expansion is primarily fueled by the increasing global incidence of cancer, the growing demand for precision medicine that offers reduced systemic toxicity, and continuous innovations in conjugation technologies. With approximately 2 million new cancer cases projected in the United States in 2024, as reported by the American Cancer Society, the urgent need for effective, targeted therapeutic solutions is clearly underscored.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 8.39 Billion
Market Size 2031	USD 12.18 Billion
CAGR 2026-2031	6.41%
Fastest Growing Segment	Monoclonal Antibodies
Largest Market	North America

However, a significant impediment to the growth of the Global Antibody Drug Conjugates Market is the inherent technical complexity and high financial investment required for manufacturing. Producing ADCs mandates highly specialized containment facilities to safely handle potent cytotoxic agents while simultaneously ensuring the stability of the biological components, which creates distinct supply chain challenges. These stringent manufacturing requirements often lead to elevated production costs and logistical constraints, potentially delaying commercialization timelines and limiting broader patient access, particularly in cost-sensitive regions.

Market Driver

A notable surge in strategic collaborations, mergers, and licensing agreements serves as a primary catalyst accelerating the Global Antibody Drug Conjugates Market. Leading pharmaceutical companies are actively acquiring clinical-stage biotech firms to integrate advanced linker technologies and next-generation payloads into their portfolios, thereby circumventing early-stage development risks. For instance, Genmab A/S announced in April 2024 its definitive agreement to acquire ProfoundBio in an all-cash transaction valued at $1.8 billion, aimed at securing rights to a portfolio of cutting-edge ADCs. This trend highlights the industry's reliance on inorganic growth strategies to rapidly scale manufacturing capabilities and secure essential intellectual property rights for future commercialization efforts.

Concurrently, the expansion of therapeutic indications into solid tumors is fundamentally reshaping market potential, extending beyond the traditional dominance of hematological malignancies. Regulatory bodies are increasingly granting approvals for targeted conjugates to treat complex conditions such as ovarian and breast cancers, driven by compelling clinical data demonstrating superior efficacy compared to standard chemotherapy. AbbVie's announcement in March 2024 confirmed the FDA's full approval for ELAHERE, specifically for patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The significant commercial viability of these solid tumor treatments is further evidenced by AstraZeneca's report that combined sales of their leading conjugate, Enhertu, recorded by the company and its partner Daiichi Sankyo, reached $2,729 million in the first nine months of 2024.

Market Challenge

The inherent technical complexity and substantial financial costs associated with manufacturing antibody drug conjugates present considerable barriers to market expansion. The production of these sophisticated therapeutics requires the precise integration of biological antibodies with potent chemical cytotoxic agents, a process that demands highly specialized containment infrastructure to ensure both safety and product stability. These rigorous requirements translate into significant capital expenditure and operational expenses, which in turn restrict the number of manufacturing facilities capable of handling such intricate production, often leading to supply chain bottlenecks and delays in product availability.

High manufacturing expenses directly influence the final pricing of these therapies, thereby rendering them less accessible in markets with constrained healthcare budgets. This economic pressure hampers the speed at which novel treatments can achieve commercial viability. The sheer scale of this logistical bottleneck is underscored by the fact that, according to the Antibody Society, more than 150 antibody drug conjugates were in active clinical development worldwide in 2024. This high volume of developmental candidates places immense strain on existing specialized manufacturing capacities, further intensifying production delays and impeding broader market growth.

Market Trends

The expansion of antibody drug conjugates (ADCs) into non-oncology therapeutic areas marks a transformative shift in the market, moving beyond the traditional focus on cancer treatment to address complex autoimmune and inflammatory diseases. Developers are strategically leveraging the precision of ADC technology to deliver potent immunomodulators directly to pathogenic immune cells, thereby minimizing the systemic toxicity often associated with broad-spectrum immunosuppressants. This strategic diversification is clearly evident in recent high-value licensing deals aimed at securing novel conjugation platforms for non-cancer indications, such as Vertex Pharmaceuticals' multi-target discovery agreement with Enlaza, valued at over $2 billion, announced in September 2025 by Fierce Biotech, to develop next-generation small-format drug conjugates specifically for autoimmune diseases, underscoring a strong commercial commitment to this emerging therapeutic frontier.

Simultaneously, the emergence of bispecific antibody-drug conjugates (BsADCs) is significantly advancing the market's technological capabilities by enabling the simultaneous targeting of two distinct tumor-associated antigens or different epitopes on the same antigen. This innovative dual-targeting mechanism not only enhances tumor selectivity and internalization rates but also holds the potential to overcome resistance mechanisms observed in monospecific formats, such as antigen loss or low expression. The clinical maturation of this modality is rapidly accelerating as developers strive to bring the first bispecific options to commercialization, with Pharmaceutical Technology reporting in August 2025 that four bispecific antibody-drug conjugate candidates were actively undergoing Phase III clinical trials, signaling their imminent regulatory review and potential market entry.

Key Market Players

Novartis AG
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Seattle Genetics Inc
Genentech Inc
Immunogen Inc
Immunomedics Inc
Progenics Pharmaceuticals Inc
Bayer HealthCare Pharmaceuticals Inc

Report Scope

In this report, the Global Antibody Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibody Drug Conjugates Market, By Types

Monoclonal Antibodies
Linker
Drug/Toxin
Others

Antibody Drug Conjugates Market, By Application

Blood Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Brain Tumor
Others

Antibody Drug Conjugates Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antibody Drug Conjugates Market.

Available Customizations:

Global Antibody Drug Conjugates Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antibody Drug Conjugates Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Types (Monoclonal Antibodies, Linker, Drug/Toxin, Others)
- 5.2.2. By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Antibody Drug Conjugates Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Types
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Antibody Drug Conjugates Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Types
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Antibody Drug Conjugates Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Types
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Antibody Drug Conjugates Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Types
    - 6.3.3.2.2. By Application

7. Europe Antibody Drug Conjugates Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Types
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Antibody Drug Conjugates Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Types
    - 7.3.1.2.2. By Application
- 7.3.2. France Antibody Drug Conjugates Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Types
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Antibody Drug Conjugates Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Types
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Antibody Drug Conjugates Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Types
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Antibody Drug Conjugates Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Types
    - 7.3.5.2.2. By Application

8. Asia Pacific Antibody Drug Conjugates Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Types
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Antibody Drug Conjugates Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Types
    - 8.3.1.2.2. By Application
- 8.3.2. India Antibody Drug Conjugates Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Types
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Antibody Drug Conjugates Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Types
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Antibody Drug Conjugates Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Types
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Antibody Drug Conjugates Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Types
    - 8.3.5.2.2. By Application

9. Middle East & Africa Antibody Drug Conjugates Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Types
- 9.2.2. By Application
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Antibody Drug Conjugates Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Types
    - 9.3.1.2.2. By Application
- 9.3.2. UAE Antibody Drug Conjugates Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Types
    - 9.3.2.2.2. By Application
- 9.3.3. South Africa Antibody Drug Conjugates Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Types
    - 9.3.3.2.2. By Application

10. South America Antibody Drug Conjugates Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Types
- 10.2.2. By Application
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Antibody Drug Conjugates Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Types
    - 10.3.1.2.2. By Application
- 10.3.2. Colombia Antibody Drug Conjugates Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Types
    - 10.3.2.2.2. By Application
- 10.3.3. Argentina Antibody Drug Conjugates Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Types
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Antibody Drug Conjugates Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd
15.3. Takeda Pharmaceutical Company Limited
15.4. Pfizer Inc.
15.5. Seattle Genetics Inc
15.6. Genentech Inc
15.7. Immunogen Inc
15.8. Immunomedics Inc
15.9. Progenics Pharmaceuticals Inc
15.10. Bayer HealthCare Pharmaceuticals Inc